Association of non-melanoma skin cancers, melanoma and merkel cell carcinoma with dermatologic medications, a case control pharmacovigilance study of the FDA Adverse Events Reporting System

Conclusions: The oral immunosuppressants and many biologic medications were associated with an increased ROR of skin cancers incl uding TNF-alpha inhibitors (etanercept, adalimumab, infliximab), IL-23 or IL 12/23 inhibitors (ustekinumab, risankizumab), and the CD-20 inhibitor rituximab, but not dupilumab or IL-17 inhibitors.
Source: Dermatology - Category: Dermatology Source Type: research